CFRX ContraFect Corporation

3.52
+0.11  (+3%)
Previous Close 3.41
Open 3.45
52 Week Low 3.05
52 Week High 7.63
Market Cap $138,451,178
Shares 39,332,721
Float 31,904,936
Enterprise Value $74,161,578
Volume 130,132
Av. Daily Volume 115,131
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Exebacase (DISRUPT)
Serious infections caused by Staph aureus including MRSA
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2021.

    "We continue to make important progress across our extensive portfolio, as we generate and publish new and compelling data highlighting the potential meaningful improvements for patients that we have observed in a variety of difficult to treat infections. Our primary focus remains on the enrollment of patients…

    YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2021.

    "We continue to make important progress across our extensive portfolio, as we generate and publish new and compelling data highlighting the potential meaningful improvements for patients that we have observed in a variety of difficult to treat infections. Our primary focus remains on the enrollment of patients in the Phase 3 DISRUPT superiority study of our Breakthrough Therapy, new modality drug, exebacase, in patients with Staph aureus bloodstream infections. We now have nearly 60 active clinical sites and we continue to accumulate patients every month, despite the ongoing COVID-19 pandemic. In addition, we remain vigilant in our financial management and will continue to provide our shareholders with relevant updates as they emerge," said Roger J. Pomerantz, M.D., President, Chief Executive Officer, and Chairman of ContraFect.

    As previously communicated, the pandemic has caused some delays in patient enrollment during certain months of this year, as hospitals struggle to recover from the surges in COVID-19 infections and hospitalizations. ContraFect now expects to conduct the planned interim futility analysis to assess the superiority of exebacase versus standard of care antibiotics (SOCA) alone, based on approximately 60% of the MRSA study population, in the first half of 2022. The Company continues to anticipate completion of full patient enrollment for the study in 2022.

    Recent Corporate Highlights

    • In October, the Company presented important new data at IDWeek 2021, in a late breaker, oral presentation, from the Phase 2 study of exebacase. These data demonstrated that exebacase, used in addition to SOCA, more rapidly resolved clinical symptoms of Staph aureus bacteremia versus SOCA alone. The median time to resolution was 3 days for exebacase-treated patients, as compared to 6 days for SOCA-alone patients. Notably, among the exebacase-treated patients with MRSA bacteremia, the median time to symptom resolution was 3 days, as compared to 7 days in patients who received SOCA alone. Additionally, 94.1% of exebacase-treated patients with MRSA bacteremia showed symptom resolution, compared with only 81.8% MRSA bacteremia patients treated with SOCA alone.



    • In October, new surveillance data was presented at IDWeek 2021 on the in vitro activity of exebacase against Staph aureus causing bacteremia in the United States, including multidrug-resistant (MDR) strains. The data showed that Staph aureus accounted for approximately 25% of all pathogens recovered from blood specimens and nearly 40% of Staph aureus infected samples were of a methicillin-resistant phenotype. These data demonstrated the potent activity of exebacase and that its activity was consistent, regardless of resistance phenotype (MSSA, MRSA, including MDR isolates).



    • In October, ContraFect announced the poster presentation on the activity of DLAs against the most prevalent MDR pathogenic strains responsible for pulmonary infections in Cystic Fibrosis patients at the North American Cystic Fibrosis Conference. The data further support the in vitro activity profile of CF-370 and amurin AM1 against specific Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Stenotrophomonas maltophilia, and Achromobacter spp.



    • In July, new data was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) demonstrating the in vitro synergy for anti-biofilm activity of exebacase with either rifampin, vancomycin, or daptomycin against Staph epidermidis strains responsible for bone and joint infections of the knee, hip and shoulder. These data add to the evidence supporting the potential for exebacase to treat Staph epidermidis infections of prosthetic joints.



    • In July, new data were presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) demonstrating the potent in vitro activity of CF-370 against clinical MDR and extreme drug-resistant (XDR) P. aeruginosa isolates, including carbapenem and colistin resistant forms. Isolates included those from the Centers for Disease Control Antibiotic Resistance Bank.

    Third Quarter 2021 Financial Results

    • Research and development (R&D) expenses were $8.7 million for the third quarter of 2021 compared to $4.7 million in the comparable period in 2020. This increase was primarily attributable to an increase in CRO and investigator site expenses related to the execution of the Phase 3 clinical study, an increase in expenditures for non-clinical studies of exebacase, CF-370, CF-296 and the amurin peptides, as all programs continued to progress forward, and an increase in clinical development and manufacturing headcount and related personnel costs to support the ongoing development of exebacase.



    • General and administrative (G&A) expenses were $3.0 million for the third quarter of 2021 compared to $2.6 million in the comparable period in 2020. This increase was primarily attributable to an increase in administrative personnel and insurance costs, which was partially offset by a decrease in legal expenses.



    • Net loss was $5.3 million, or a loss of $(0.13) per share, for the third quarter of 2021 compared to net income of $3.4 million, or income of $0.12 per share, for the comparable period in 2020. The net loss per share in the current period includes a $6.4 million, or $0.16 per share, non-cash gain from the change in the fair value of the Company's warrant liabilities. In the prior year period, the net income per share included a $10.7 million, or $0.38 per share, non-cash gain from the change in the fair value of the Company's warrant liabilities.



    • As of September 30, 2021, ContraFect had cash, cash equivalents and marketable securities of $63.3 million.

    About Exebacase (CF-301):

    Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of bloodstream infections (BSIs) also known as bacteremia. In the Company's Phase 2 study of exebacase, a pre-specified analysis of MRSA-infected patients showed that the clinical responder rate at Day 14 in patients treated with exebacase was nearly 43-percentage points higher than in patients treated with SOC antibiotics alone (74.1% for patients treated with exebacase compared to 31.3% for patients treated with SOC antibiotics alone (p=0.010)). In addition to the higher rate of clinical response, MRSA-infected patients treated with exebacase showed a 21-percentage point reduction in 30-day all-cause mortality (p=0.056), a four-day lower median length of hospital stay and meaningful reductions in hospital readmission rates. Exebacase is currently being studied in the Phase 3 DISRUPT superiority design study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.

    Exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia. Exebacase was licensed from The Rockefeller University and is being developed at ContraFect.

    About CF-370:

    CF-370 is an investigational first-in-class therapeutic candidate targeting P. aeruginosa, a Gram-negative pathogen. CF-370 has been engineered to bypass the outer membrane of the bacteria and to enable potent activity in human serum. The Company believes this is a significant milestone for direct lytic agents as native lysins are typically unable to penetrate the outer membrane of Gram-negative bacteria. However, based on the proprietary methods the Company has identified and utilizes to engineer lysins, CF-370 has exhibited the microbiologic attributes of the lysin class, including rapid and potent bactericidal activity, synergy with a broad range of standard of care antibiotics and the eradication of biofilms in preclinical studies. The promising data from animal models support the potential therapeutic utility of CF-370 for the treatment of serious infections caused by P. aeruginosa.

    About ContraFect:

    ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.

    Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.

    Activities related to exebacase during the period of performance under the contract will be funded in part with federal funds from HHS; ASPR; BARDA, under contract number 75A501212C00021.

    Forward-Looking Statements

    This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: the Company's progress across its portfolio, data, study patient enrollment, delays and expected timelines, the disclosure of relevant updates, COVID-19, timing of the interim futility analysis, in vivo and in vitro results, presentations, the Company's financial results, financial position, balance sheets and statements of operations, ContraFect's ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, whether ContraFect will address life-threatening infections using its DLA platform, whether exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia, the features, properties and potential utility of CF-370, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect's lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect's product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection and other important risks detailed under the caption "Risk Factors" in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.





    CONTRAFECT CORPORATION


    Condensed Balance Sheets

    (in thousands)
       
     September 30,

    2021

     December 31,

    2020

     (unaudited) (audited)
    Assets  
    Current assets:  
    Cash and cash equivalents        $20,225 $15,485
    Marketable securities         43,092  27,005
    Prepaid expenses and other current assets         11,022  4,165
       
    Total current assets         74,339  46,655
    Property and equipment, net         784  910
    Operating lease right-of-use assets         2,614  2,811
    Other assets         105  740
       
    Total assets        $77,842 $51,116
       
       
    Liabilities and stockholders' equity  
    Current liabilities        $9,869 $6,060
    Warrant liabilities         12,194  29,404
    Long-term portion of lease liabilities         2,700  2,959
    Other liabilities         73  73
    Total liabilities         24,836  38,496
    Total stockholders' equity         53,006  12,620
    Total liabilities and stockholders' equity        $77,842 $51,116
       





    CONTRAFECT CORPORATION


    Unaudited Statements of Operations

    (in thousands, except share and per-share data)
         
     Three Months Ended September 30,

     Nine Months Ended September 30,

      2021    2020

      2021    2020

    Operating expenses:    
    Research and development$8,664  $4,706  $24,462  $15,354 
    General and administrative 3,022   2,607   8,722   8,186 
         
    Total operating expenses 11,686   7,313   33,184   23,540 
         
    Loss from operations         (11,686)  (7,313)  (33,184)  (23,540)
    Other income (expense):    
    Interest income 36   58   91   154 
    Other income (expense)    10      (2,165)
    Change in fair value of warrant liabilities 6,358   10,689   17,210   3,800 
         
    Total other income 6,394   10,757   17,301   1,789 
         
    Net income (loss)$(5,292) $3,444  $(15,883) $(21,751)
         
    Per share information:    
    Basic net income (loss) per share         $    (0.13) $0.12  $    (0.44) $    (1.03)
         

    (in thousands, except share and per-share data)

     Three Months Ended September 30,  Nine Months Ended September 30, 
      2021   2020   2021   2020 
    Shares used in computing basic net income (loss) per share 39,332,721   27,809,169   35,914,327   21,069,057 
                    
    Diluted net loss per share        $(0.13) $(0.19) $    (0.44) $    (1.03)
    Shares used in computing diluted net loss per share         39,332,721   29,079,107   35,914,327   21,069,057 
         

    In this release, management has presented its financial position as of September 30, 2021 and its operating results for the three and nine months ended September 30, 2021 and 2020 in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The Company's financial position as of December 31, 2020 has been extracted from the Company's audited financial statements included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2021. You should refer to both the Company's Quarterly Report on Form 10-Q and its Annual Report on Form 10-K for a complete discussion of financial information.

    Investor Relations Contacts:

    Michael Messinger

    ContraFect Corporation

    Tel: 914-207-2300

    Email:

    Jules Abraham

    CORE IR

    Tel: 917-885-7378



    Primary Logo

    View Full Article Hide Full Article
  2. YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that data from the Company's DLA programs, including lysin CF-370 and amurin peptide AM1, demonstrate the potential for their development as treatments for pulmonary infections associated with cystic fibrosis. These data were recently presented at the North American Cystic Fibrosis Conference (NACFC) which was held virtually from November 2-5, 2021.

    These direct lytic agents show in vitro

    YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that data from the Company's DLA programs, including lysin CF-370 and amurin peptide AM1, demonstrate the potential for their development as treatments for pulmonary infections associated with cystic fibrosis. These data were recently presented at the North American Cystic Fibrosis Conference (NACFC) which was held virtually from November 2-5, 2021.

    These direct lytic agents show in vitro activity against the most prevalent Gram-negative pathogens, including multi-drug resistant (MDR) strains commonly associated with pulmonary infections in patients with cystic fibrosis. Nine of these MDR strains were evaluated. Currently, few treatment options exist to address these infections, and persons with cystic fibrosis are even more vulnerable. The data further support the in vitro activity profile of CF-370 and AM1 against specific Gram-negative pathogens, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter spp.

    Raymond Schuch, Ph.D., Vice President, Research, ContraFect Corporation, delivered the poster presentation entitled "Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans". The presentation is available on the Company's website.

    About Cystic Fibrosis

    According to the Cystic Fibrosis (CF) Foundation, infections are a problem for people with cystic fibrosis because they can cause fever, difficulty breathing, coughing, and excessive inflammation. A cycle of recurring infections and inflammation gradually destroys lung tissue. People with CF are susceptible to infections from bacteria, viruses, and fungi because abnormally thick, sticky mucus traps these germs in the airways. They also are prone to infections because their mucus and airway liquid does not have the same infection-fighting properties as normal mucus. This abnormal mucus provides an ideal environment for bacteria to form protective layers -- known as biofilms -- that make them more difficult to kill. For more information visit: https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/

    About Exebacase (CF-301):

    Exebacase is an anti-staphylococcal recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of bloodstream infections (BSIs) also known as bacteremia. It is the first lysin to enter clinical studies in the U.S. and was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to standard of care (SOC) anti-staphylococcal antibiotics.

    Exebacase is currently being studied in the Phase 3 DISRUPT superiority design study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis. In the Company's Phase 2 study of exebacase, a pre-specified analysis of MRSA-infected patients showed that the clinical responder rate at Day 14 in patients treated with exebacase was nearly 43-percentage points higher than in patients treated with SOC antibiotics alone (74.1% for patients treated with exebacase compared to 31.3% for patients treated with SOC antibiotics alone (p=0.010)). In addition to the higher rate of clinical response, MRSA-infected patients treated with exebacase showed a 21-percentage point reduction in 30-day all-cause mortality (p=0.056), a four-day lower median length of hospital stay and meaningful reductions in hospital readmission rates.

    Exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia. The lysin was licensed from The Rockefeller University and is being developed at ContraFect.

    About ContraFect

    ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosaAcinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as methicillin-resistant Staph aures (MRSA) and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.

    Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.

    Forward-Looking Statements

    This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: the in-vitro activity of DLAs and their potential to treat pulmonary infections associated with cystic fibrosis, ContraFect's ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, whether ContraFect will address life-threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect's lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect's product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection and other important risks detailed under the caption "Risk Factors" in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    Investor Relations Contacts:

    Michael Messinger

    ContraFect Corporation

    Tel: 914-207-2300

    Email:

    Jules Abraham

    CORE IR

    Tel: 917-885-7378

    Email:



    Primary Logo

    View Full Article Hide Full Article
  3. YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces it will be presenting a poster on the activity of DLAs against common Gram-negative pathogens responsible for pulmonary infections in Cystic Fibrosis patients at the North American Cystic Fibrosis Conference, which will be held virtually from November 2-5, 2021.

    Poster presentation at NACFC 2021:

    Poster Title: Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections

    YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces it will be presenting a poster on the activity of DLAs against common Gram-negative pathogens responsible for pulmonary infections in Cystic Fibrosis patients at the North American Cystic Fibrosis Conference, which will be held virtually from November 2-5, 2021.

    Poster presentation at NACFC 2021:

    Poster Title: Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans.

    Poster Number and Session: Poster 573

    Date: November 2, 2021

    Presenting Author: Raymond Schuch, Ph.D., Vice President, Research

    Following the meeting, the presentation poster will be available on the ContraFect website.

    About ContraFect

    ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosaAcinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as methicillin-resistant Staph aureus (MRSA) and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to standard-of-care anti-staphylococcal antibiotics.

    Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.

    Forward-Looking Statements

    This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: the activity of DLAs and their potential to treat Cystic Fibrosis, ContraFect's ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, whether ContraFect will address life-threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect's lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect's product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection and other important risks detailed under the caption "Risk Factors" in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.



    Investor Relations Contacts:

    Michael Messinger

    ContraFect Corporation

    Tel: 914-207-2300

    Email:  

    Jules Abraham

    CORE IR

    Tel: 917-885-7378

    Email:  



    Primary Logo

    View Full Article Hide Full Article
  4. YONKERS, New York, Oct. 04, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today new data from the Company's Phase 2 study of exebacase demonstrating rapid symptom resolution among patients with Staphylococcus aureus (Staph aureus) bacteremia. These data were recently presented as a Late Breaker oral presentation at IDWeek™ 2021, that was held from September 29 through October 3, in San Diego, CA.

    "The important, new data presented at IDWeek is further detailed…

    YONKERS, New York, Oct. 04, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today new data from the Company's Phase 2 study of exebacase demonstrating rapid symptom resolution among patients with Staphylococcus aureus (Staph aureus) bacteremia. These data were recently presented as a Late Breaker oral presentation at IDWeek™ 2021, that was held from September 29 through October 3, in San Diego, CA.

    "The important, new data presented at IDWeek is further detailed validation of the potential utility of exebacase in such pernicious infections, and it clearly demonstrates rapid and meaningful symptom resolution when exebacase is added to standard of care antibiotics. This is especially important as the options for treating serious bloodstream infections, such as those caused by MRSA, continue to be few, with exebacase being one of the few new modalities being developed for these types of infections," stated Cara Cassino, M.D., ContraFect's Chief Medical Officer and Executive Vice President of Research & Development.

    Staph aureus is a leading cause of infections in US healthcare facilities. Any Staph infection can be deadly. Staph aureus infections can be either methicillin-resistant (MRSA) or methicillin-susceptible (MSSA). MRSA infections are particularly difficult to treat because of their resistance to antibiotics, increasing virulence and patient comorbidities.

    The oral data presentation, Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus Bacteremia, demonstrated that exebacase, used in addition to standard of care antibiotics (SOCA), more rapidly resolved symptoms of Staph aureus bacteremia versus SOCA alone.

    Specifically, the data show:

    • 86 patients with Staph aureus bacteremia, including endocarditis, had at least one symptom present at baseline (53 patients in the exebacase+SOCA group and 33 SOCA-alone patients). Symptoms resolved in the majority of these patients (94.3% in the exebacase-treated group versus 87.9% of SOCA-alone patients).



    • The median time to resolution was 3 days for exebacase-treated patients compared to 6 days for SOCA-alone patients.
    • MRSA: The median time to symptom resolution in patients with MRSA bacteremia was 3 days in exebacase-treated patients, as compared to 7 days in patients who received SOCA alone.



      Among the exebacase-treated patients with MRSA bacteremia, 94.1% showed symptom resolution compared with 81.8% of SOCA-alone patients.

    • MSSA: The median time to symptom resolution in patients with MSSA bacteremia was 3 days in exebacase-treated patients, as compared to 6 days in patients who received SOCA alone.

    Time to resolution of symptoms was analyzed using Kaplan-Meier methods. For those symptoms (shortness of breath, sweating, fatigue and/or confusion) present at baseline and attributable to the bacteremia, time to resolution of symptoms was defined as the number of days until all attributable symptoms were absent.

    About Exebacase (CF-301):

    Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of bloodstream infections (BSIs) also known as bacteremia. In the Company's Phase 2 study of exebacase, a pre-specified analysis of MRSA-infected patients showed that the clinical responder rate at Day 14 in patients treated with exebacase was nearly 43-percentage points higher than in patients treated with SOC antibiotics alone (74.1% for patients treated with exebacase compared to 31.3% for patients treated with SOC antibiotics alone (p=0.010)). In addition to the higher rate of clinical response, MRSA-infected patients treated with exebacase showed a 21-percentage point reduction in 30-day all-cause mortality (p=0.056), a four-day lower median length of hospital stay and meaningful reductions in hospital readmission rates. Exebacase was well-tolerated and treatment emergent adverse events, including serious treatment-emergent serious adverse events (SAEs) were balanced between the treatment groups. There were no SAEs determined to be related to exebacase, there were no reports of hypersensitivity related to exebacase and no patients discontinued treatment with study drug in either treatment group.

    Exebacase is currently being studied in the Phase 3 DISRUPT superiority design study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.

    Exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia. The lysin was licensed from The Rockefeller University and is being developed at ContraFect.

    About ContraFect

    ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosaAcinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.

    Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.

    Forward-Looking Statements

    This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: exebacase data, including its clinical utility and symptom resolution, ContraFect's ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, whether exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia, whether ContraFect will address life-threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect's lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect's product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection and other important risks detailed under the caption "Risk Factors" in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.



    Investor Relations Contacts:

    Michael Messinger

    ContraFect Corporation

    Tel: 914-207-2300

    Jules Abraham

    CORE IR

    Tel: 917-885-7378



    Primary Logo

    View Full Article Hide Full Article
  5. YONKERS, N.Y., Sept. 29, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected to deliver a Late Breaker oral presentation on the rapid symptom resolution in adult patients with Staphylococcus aureus (Staph aureus) bacteremia who were treated with exebacase in the completed Phase 2 study.

    The company will also present the results of a recently conducted microbiologic surveillance study of the activity of exebacase (CF-301) against…

    YONKERS, N.Y., Sept. 29, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected to deliver a Late Breaker oral presentation on the rapid symptom resolution in adult patients with Staphylococcus aureus (Staph aureus) bacteremia who were treated with exebacase in the completed Phase 2 study.

    The company will also present the results of a recently conducted microbiologic surveillance study of the activity of exebacase (CF-301) against Staph aureus specimens from patients with bacteremia in the United States, including multidrug-resistant Methicillin-resistant Staph aureus (MRSA) species.

    These findings are all being presented at IDWeekTM 2021, being held from September 29 through October 3, in San Diego, CA.

    IDWeekTM 2021 Presentation Details:

    Oral Late-Breaker presentation:

    Abstract: Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus bacteremia

    Session: Late Breaker Abstracts

    Date: Saturday October 2, 2021

    Session Time: 1:15 PM – 3:00 PM

    Presenting Author: Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research & Development, ContraFect

    Poster presentation:

    Session: Novel Agents

    Poster Title: In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-resistant Subsets 

    Poster ID: 1059

    Presenting Author: Rodrigo Mendes, Ph.D. (JMI Laboratories)

    All posters will be available to meeting registrants on demand and available through the IDWeek website. Following the meeting, the presentation abstracts and poster will be available on the ContraFect website.

    About Exebacase (CF-301):

    Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of bloodstream infections (BSIs) also known as bacteremia. In the Company's Phase 2 study of exebacase, a pre-specified analysis of MRSA-infected patients showed that the clinical responder rate at Day 14 in patients treated with exebacase was nearly 43-percentage points higher than in patients treated with SOC antibiotics alone (74.1% for patients treated with exebacase compared to 31.3% for patients treated with SOC antibiotics alone (p=0.010)). In addition to the higher rate of clinical response, MRSA-infected patients treated with exebacase showed a 21-percentage point reduction in 30-day all-cause mortality (p=0.056), a four-day lower median length of hospital stay and meaningful reductions in hospital readmission rates. Exebacase is currently being studied in the Phase 3 DISRUPT superiority design study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.

    Exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia. Exebacase was licensed from The Rockefeller University and is being developed at ContraFect.

    About ContraFect

    ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosaAcinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.

    Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.

    Forward-Looking Statements

    This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: exebacase data and its clinical utility, the presentations, ContraFect's ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, whether exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia, whether ContraFect will address life-threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect's lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect's product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection and other important risks detailed under the caption "Risk Factors" in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.



    Investor Relations Contacts:

    Michael Messinger

    ContraFect Corporation

    Tel: 914-207-2300

    Jules Abraham

    CORE IR

    Tel: 917-885-7378



    Primary Logo

    View Full Article Hide Full Article
View All ContraFect Corporation News